{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.7"},{"groupId":"OG001","value":"29.1"}]}],"title":"Hemoglobin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.8"},{"groupId":"OG001","value":"21.8"}]}],"title":"Platelets"}],"denoms":[{"counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"289"}],"units":"Participants"}],"description":"Sustained hematologic improvement was defined as hematological improvement that was sustained continuously for greater than or equal to (\\>=) 56 days without blood transfusion or growth factors: 1) Platelet counts greater than (\\>)100\\* 109/liter (L) if baseline less than or equal to (\\<=) 100\\*109/L or increase \\>= 50 percent (%) over baseline; 2) Hemoglobin \\>11 gram per deciliters (g/dL) if baseline \\<= 11 g/dL or increase \\>= 2 g/dL over baseline.","groups":[{"description":"Participants received ibrutinib 420 milligram (mg) (3 \\* 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.","id":"OG000","title":"Ibrutinib+BR"},{"description":"Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.","id":"OG001","title":"Placebo+BR"}],"paramType":"NUMBER","populationDescription":"ITT population included all participants randomized into the study regardless of treatment actually received.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Percentage of Participants With Sustained Hematologic Improvement","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}